| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8784911 | Advances in Radiation Oncology | 2017 | 20 Pages |
Abstract
FSRT for brain metastases appears to demonstrate a high rate of local control with minimal risk of severe toxicity. Local control appears to be associated with smaller tumor sizeand a higher prescription dose. FSRT is a viable option for those who are poor single-fraction candidates.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Samuel R. MD, Andrew M. MD, Jonathan W. MD, Richard A. PhD, Kristen O. MD, James M. MD, Christopher D. MD, PhD, Markus MD, PhD, John B. MD,